Please login to the form below

Not currently logged in

Valeant buys Sanofi's dermatology unit

Sanofi has said it is to sell its Dermik dermatology unit to Canada-based Valeant Pharmaceuticals for $425m

Sanofi has said it is to sell its Dermik dermatology unit to Canada-based Valeant Pharmaceuticals for $425m.

Dermik operates in the US and Canada, and has a portfolio that includes Benzaclin (benzoyl peroxide/clindamycin) for the treatment of acne; Carac (fluorouracil cream) for the treatment of keratoses; and Sculptra (poly-L-lactic acid), a facial injectable for wrinkles.

Valeant will obtain all Dermik assets, including available inventories of approximately $18m, which consist of an aesthetic and therapeutic business in the United States and Canada, as well as a widely dispersed aesthetic business around the world.

Valeant will also acquire Sanofi's manufacturing site in Laval, Canada.

Sanofi said it has decided to sell its dermatology business to concentrate on other areas of growth.

"This divestiture allows us to rationalise our portfolio and improve focus on our core businesses," said Christopher A Viehbacher, CEO, Sanofi. "Our manufacturing operations in Laval and our field operations teams will benefit from Valeant's stronger presence in dermatology."

11th July 2011


Featured jobs

Subscribe to our email news alerts


Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...